logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
Journal Article
|Research

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Wassuna M, Njenga SN, Balasegaram M, Alexander N, Omollo R, Edwards T, Dorlo TPC, Musa B, Sharaf Ali MH, Elamin MY, Kirigi G, Juma R, Kip AE, Schoone GJ, Hailu ADE, Olobo J, Ellis SJ, Kimutai R, Wells S, Gasim Khalil EA, Wourgaft NS, Alves F, Musa AM
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa.

Subject Area

infections, other

Languages

English
DOI
10.1371/journal.pntd.0004880
Published Date
14 Sep 2016
PubMed ID
27627654
Journal
PLOS Neglected Tropical Diseases
Volume | Issue | Pages
Volume 10, Issue 9
Issue Date
2016-09-14
Dimensions Badge
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial | Journal Article / Research | MSF Science Portal